Newsweek

Firm Founded by a Trump Nominee Violated Trading Rules

A review of U.S. market regulatory filings raises questions about Virtu Financial, Vincent Viola’s high-frequency trading firm.
Vincent Viola enters Trump Tower in New York City, December 16.
0104_vincent_viola_01

Virtu Financial, the giant Wall Street high-frequency trading firm run by President-elect Donald Trump’s nominee for secretary of the Army, Vincent Viola, has a record of violating the rules of the U.S. Securities Exchange Act, the Nasdaq Stock Market, the New York Stock Exchange and other exchanges that extends back nearly as long as the firm has been in business, according to U.S. market regulatory filings reviewed by Newsweek.

The , dated December 20—just one day after Trump nominated Viola to take charge of the Army’s weapons systems, personnel, finances and other key functions—shows that Virtu, which Viola founded in 2008, quietly settled—occurring between December 2010 and July 2012—that had previously not been made public and for which Virtu had received a cautionary letter from the exchange. The latest filing shows that the NYSE’s warning apparently went unheeded, with many of the same types of trading violations and failures to supervise staff and business practices taking place for years at the firm.

You’re reading a preview, subscribe to read more.

More from Newsweek

Newsweek12 min read
The Inconceivable Search For Sperm
SINGLE WOMEN AND LGBTQ+ COUPLES are increasingly pursuing pregnancy via known donors—people they find on the internet, in Facebook groups and through dating-like apps. In her own quest to become a solo mother by choice, investigative journalist Valer
Newsweek3 min read
Newsweek US
GLOBAL EDITOR IN CHIEF _ Nancy Cooper VICE PRESIDENT, DIGITAL _ Laura Davis DIRECTOR OF OPERATIONS _ Melissa Jewsbury OPINION EDITOR _ Batya Ungar-Sargon GLOBAL PUBLISHING EDITOR _ Chris Roberts SENIOR EDITOR-AT-LARGE _ Josh Hammer EDITORIAL Managi
Newsweek5 min read
‘Deadly Risk’ of Fat-Loss Drugs
“MIRACLE” FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned. The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2

Related